CARGO Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRGX research report →
Companycargo-tx.com
CARGO Therapeutics, Inc. , a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
- CEO
- Anup Radhakrishnan
- IPO
- 2023
- Employees
- 167
- HQ
- San Mateo, DE, US
Price Chart
Valuation
- Market Cap
- $216.19M
- P/E
- -1.20
- P/S
- 27.61
- P/B
- 0.91
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -40.29%
- Op Margin
- -2445.19%
- Net Margin
- -2297.19%
- ROE
- -61.29%
- ROIC
- -80.35%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-167,502,000 · -70.66%
- EPS
- $-3.72 · -56.30%
- Op Income
- $-187,370,000
- FCF YoY
- -59.93%
Performance & Tape
- 52W High
- $25.45
- 52W Low
- $3.00
- 50D MA
- $4.45
- 200D MA
- $7.81
- Beta
- 0.29
- Avg Volume
- 1.68M
Get TickerSpark's AI analysis on CRGX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 25 | Dhingra Kapil | sell | 25,000 |
| Aug 19, 25 | Viswanadhan Krishnan | sell | 25,000 |
| Aug 19, 25 | Viswanadhan Krishnan | sell | 3,173 |
| Aug 19, 25 | Lubner David Charles | sell | 25,000 |
| Aug 19, 25 | Orwin John A | sell | 15,865 |
| Aug 19, 25 | Orwin John A | sell | 25,000 |
| Aug 19, 25 | Henderson Jane | sell | 25,000 |
| Aug 19, 25 | Bassan Abraham | sell | 25,000 |
| Aug 19, 25 | Huber Reid M | sell | 25,000 |
| Aug 18, 25 | Radhakrishnan Anup | other | 57,345 |
Our CRGX Coverage
We haven't published any research on CRGX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRGX Report →